Todd C. Zankel
Keine laufenden Positionen mehr
Karriereverlauf von Todd C. Zankel
Ehemalige bekannte Positionen von Todd C. Zankel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2009 | 01.10.2009 |
| Gründer | 01.10.2009 | 01.10.2009 | |
| BIOMARIN PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 | 01.01.2005 |
| RAPTOR PHARMACEUTICAL CORP | Gründer | 29.09.2009 | - |
| Raptor Pharmaceutical, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | - |
| Gründer | 24.11.2010 | - |
Ausbildung von Todd C. Zankel
| The Reed Institute | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Raptor Pharmaceutical, Inc. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
- Börse
- Insiders
- Todd C. Zankel
- Erfahrung
